Evolving applications of liquid biopsies in gastrointestinal cancers.

IF 1.1 Q4 ONCOLOGY Clinical Advances in Hematology & Oncology Pub Date : 2024-01-01
Peter Li, Christian Agbisit, Marcus Noel, Reetu Mukherji
{"title":"Evolving applications of liquid biopsies in gastrointestinal cancers.","authors":"Peter Li, Christian Agbisit, Marcus Noel, Reetu Mukherji","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Liquid biopsy is a test that allows for the diagnosis and analysis of cancer by sampling cancer cells or byproducts present in biological fluids such as blood or urine. It has the potential to create a new paradigm in oncologic care, being a less invasive approach than conventional tissue biopsy. Liquid biopsy has multifaceted applications for longitudinal disease monitoring in terms of surveillance, treatment response, and identification of emerging resistance mechanisms. Multiple assays currently exist or are in development for detecting circulating tumor cells, DNA, RNA, exosomes, proteins, fragmentomic markers, and metabolomes. Here, we review the applications of liquid biopsy in gastrointestinal cancers, emphasizing its use in both perioperative and advanced settings. We also examine its role in screening, diagnostics, and other cancer-related scenarios.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"22 1","pages":"43-54"},"PeriodicalIF":1.1000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Advances in Hematology & Oncology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Liquid biopsy is a test that allows for the diagnosis and analysis of cancer by sampling cancer cells or byproducts present in biological fluids such as blood or urine. It has the potential to create a new paradigm in oncologic care, being a less invasive approach than conventional tissue biopsy. Liquid biopsy has multifaceted applications for longitudinal disease monitoring in terms of surveillance, treatment response, and identification of emerging resistance mechanisms. Multiple assays currently exist or are in development for detecting circulating tumor cells, DNA, RNA, exosomes, proteins, fragmentomic markers, and metabolomes. Here, we review the applications of liquid biopsy in gastrointestinal cancers, emphasizing its use in both perioperative and advanced settings. We also examine its role in screening, diagnostics, and other cancer-related scenarios.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
液体活检在胃肠道癌症中的应用不断发展。
液体活检是一种通过对血液或尿液等生物液体中的癌细胞或副产品进行采样,从而诊断和分析癌症的检测方法。与传统的组织活检相比,液体活检的创伤性更小,有可能开创肿瘤治疗的新模式。液体活检在纵向疾病监测、治疗反应和识别新出现的抗药性机制方面有多方面的应用。目前已有或正在开发多种检测方法,用于检测循环肿瘤细胞、DNA、RNA、外泌体、蛋白质、片段组标记物和代谢组。在此,我们将回顾液体活检在胃肠道癌症中的应用,强调其在围手术期和晚期的应用。我们还探讨了液体活检在筛查、诊断和其他癌症相关应用中的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.10
自引率
0.00%
发文量
99
期刊介绍: Clinical Advances in Hematology & Oncology (CAH&O) is a monthly peer-reviewed journal reaching more than 27,000 hematology and oncology clinicians. CAH&O provides editorial content encompassing a wide array of topics relevant and useful to the fields of oncology and hematology, both separately and together. Content is directed by the strong input of today’s top thought leaders in hematology & oncology, including feature-length review articles, monthly columns consisting of engaging interviews with experts on current issues in solid tumor oncology, hematologic malignancies, hematologic disorders, drug development, and clinical case studies with expert commentary. CAH&O also publishes industry-supported meeting highlights, clinical roundtable monographs, and clinical review supplements.
期刊最新文献
Recombinant ADAMTS13 concentrate in thrombotic thrombocytopenic purpura. Should ponatinib be the standard-of-care tyrosine kinase inhibitor in Ph+ ALL? Does combination menopausal hormone therapy increase the risk of breast cancer? Tackling the cancer drug shortage. Targeted therapy in prostate cancer: beyond PSMA.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1